Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Maxcyte Inc (NQ: MXCT ) 3.720 -0.160 (-4.12%) Streaming Delayed Price Updated: 2:31 PM EDT, Oct 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Maxcyte Inc < Previous 1 2 Next > MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases September 16, 2024 Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference September 05, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance August 06, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 July 09, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference May 29, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development May 22, 2024 Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... From MaxCyte, Inc Via GlobeNewswire MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance May 07, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 April 10, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) April 02, 2024 Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs From MaxCyte, Inc Via GlobeNewswire MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance March 12, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results March 04, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences February 09, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers January 30, 2024 Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 23, 2024 Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer... From MaxCyte, Inc Via GlobeNewswire MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results January 08, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline January 03, 2024 Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. From MaxCyte, Inc; Lion TCR Via GlobeNewswire MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director January 02, 2024 From MaxCyte, Inc Via GlobeNewswire MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 December 11, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member November 16, 2023 MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines From MaxCyte, Inc Via GlobeNewswire MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance November 08, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Two Upcoming Investor Conferences November 06, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance October 04, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing September 06, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Baird Global Healthcare Conference September 05, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance August 09, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients August 01, 2023 Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative... From MaxCyte, Inc Via GlobeNewswire MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 July 13, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies July 10, 2023 MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. From MaxCyte, Inc Via GlobeNewswire MaxCyte Signs Strategic Platform License with Lyell Immunopharma July 06, 2023 From MaxCyte, Inc Via GlobeNewswire MaxCyte to Participate in Upcoming Investor Conferences June 01, 2023 From MaxCyte, Inc Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.